Gosatuzumab (Todavi) full leaflet analysis and dosage guidelines

Gosatuzumab (Trodelvy, trade name: Trodelvy) is an antibody-drug conjugate (ADC), mainly used to treat patients with advanced or metastatic urothelial cancer and triple-negative breast cancer. As a new type of targeted therapy drug, gosatuzumab combines the specificity of antibodies and the lethality of cytotoxicity to achieve precise killing of tumor cells. The following will provide a detailed analysis of its instructions and usage guidelines to help patients and medical staff fully understand the key points of using this drug.

1. Drug composition and mechanism of action

Gosatuzumab consists of a monoclonal antibody directed against the TROP-2 receptor conjugated via a linker to the cytotoxic SN-38 (the active metabolite of irinotecan). TROP-2 is a protein highly expressed on the surface of a variety of solid tumor cells. Gosatuzumab can selectively bind to TROP-2 positive tumor cells, accurately deliver cytotoxins into tumor cells, induce DNA damage, and promote tumor cell apoptosis. This mechanism achieves efficient targeted killing of drugs while reducing damage to normal tissues.

2. Indications

According to the instructions, gosatuzumab is mainly suitable for:

Patients with locally advanced or metastatic urothelial carcinoma who have failed at least one line of systemic chemotherapy.

Patients with metastatic triple-negative breast cancer (TNBC) who have previously received chemotherapy and have disease progression.

Gosatuzumab brings new therapeutic hope to patient populations in these two indications that often lack effective treatment options.

3. Usage, Dosage and Taking Guidelines

Gosatuzumab is administered by intravenous infusion. The recommended dose is 10 mg/kg per cycle, based on 21 days as one cycle, intravenous infusion on day 1 and day 8. The infusion time is generally controlled at 30-40 minutes. When taking the drug for the first time, medical staff need to closely observe the patient for infusion-related reactions.

Patients should be closely monitored during treatment, including hematological parameters (such as neutrophil count), liver and kidney function, and possible adverse reactions. If severe bone marrow suppression, abnormal liver function or other serious adverse events occur, the dose must be adjusted or the drug temporarily discontinued according to the guidance of a doctor. During medication, avoid combining it with drugs that affect liver enzymes to prevent abnormal drug metabolism.

4. Adverse reactions and precautions

Common adverse reactions include bone marrow suppression (such as neutropenia), fatigue, nausea, alopecia, diarrhea, and rash. Some patients may experience infusion-related reactions, such as fever, chills, difficulty breathing, etc., and anti-allergic drugs and supportive treatment need to be prepared in advance.

During use, patients should regularly review their blood images and liver and kidney functions, and report any abnormal symptoms in a timely manner. For pregnant and lactating women, you need to weigh the pros and cons and follow your doctor's advice when using this drug.

In summary, gosatuzumab (Todavi), as an innovative antibody-conjugated drug, provides a new treatment option for patients with urothelial carcinoma and triple-negative breast cancer. Standardized medication operations and strict safety monitoring are the keys to ensuring treatment effectiveness and patient safety. Patients should strictly follow the doctor's instructions and undergo relevant examinations regularly to ensure that the drug's efficacy is maximized and the quality of life is improved.

Reference materials:https://www.drugs.com